Drug Information

Drug (ID: DG01821) and It's Reported Resistant Information

• Name: IWP 4
• Synonyms: 686772-17-8; IWP-4; IWP 4; wnt inhibitor iwp-4; 2-((3-(2-methoxyphenyl)-4-oxo-3,4,6,7-tetrahydrothieno[3,2-d]pyrimidin-2-yl)thio)-N-(6-methylbenzo[d]thiazol-2-yl)acetamide; CHEMBL1257090; N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-3-(2-methoxyphenyl)-4-oxothieno[3,2-d]pyrimidin-2-yl)thio]-acetamide; N-(6-Methylbenzo[d]thiazol-2-yl)-2-(3-(2-methoxyphenyl)-4-oxo-3,4,6,7-tetrahydrothieno[3,2-d]pyrimidin-2-ylthio)acetamide; Inhibitor of Wnt Production-4; SCHEMBL12571760; C26H29ClN2O4S.H3PO4; EX-A2455; ZINC2719825; BDBM50428027; MFCD04457754; AKOS024584894; MCULE-3532196300; IWP-4, >=95% (HPLC); NCGC00387247-04; 2-[[3-(2-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-N-(6-methyl-1,3-benzothiazol-2-yl)acetamide; AC-33202; AS-35152; BI162786; HY-12879; CS-0012738; EU-0088918; AB00668741-01; F0579-0237; N-[2-[[[3-(4-Chlorophenyl)-2-propen yl]methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4 -methoxybenzenesulphonamide phosphate
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Laryngeal cancer [ICD-11: 2C23]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 6
• IsoSMILES: CC1=CC2=C(C=C1)N=C(S2)NC(=O)CSC3=NC4=C(C(=O)N3C5=CC=CC=C5OC)SCC4
• InChI: InChI=1S/C23H20N4O3S3/c1-13-7-8-14-18(11-13)33-22(24-14)26-19(28)12-32-23-25-15-9-10-31-20(15)21(29)27(23)16-5-3-4-6-17(16)30-2/h3-8,11H,9-10,12H2,1-2H3,(H,24,26,28)
• InChIKey: RHUJMHOIQBDFQR-UHFFFAOYSA-N
• PubChem CID: 2155264

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Laryngeal cancer [ICD-11: 2C23]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Urothelial cancer associated 1 (UCA1) [1]

• Molecule Alteration: Up-regulation; Expression
• Resistant Disease: Laryngeal carcinoma [ICD-11: 2C23.0]
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: Wnt/Beta-catenin signaling pathway; Activation; hsa04310
• In Vitro Model: AMC-HN-8 cells; Larynx; Homo sapiens (Human); CVCL_5966
• Experiment for Molecule Alteration: qRT-PCR; Western bloting analysis; Knockdown assay; Overexpression assay
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: UCA1 overexpression promoted, whereas UCA1 knockdown inhibited the proliferation, migration and invasion of LSCC cells.

References

• Ref 1: Silence of lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells. J Cell Biochem. 2019 Jun;120(6):9243-9249. doi: 10.1002/jcb.28200. Epub 2019 Jan 16.